HK1212225A1 - Therapeutic formulation and methods of treatment - Google Patents

Therapeutic formulation and methods of treatment Download PDF

Info

Publication number
HK1212225A1
HK1212225A1 HK16100185.7A HK16100185A HK1212225A1 HK 1212225 A1 HK1212225 A1 HK 1212225A1 HK 16100185 A HK16100185 A HK 16100185A HK 1212225 A1 HK1212225 A1 HK 1212225A1
Authority
HK
Hong Kong
Prior art keywords
formulation
hydralazine
amount
added
macular degeneration
Prior art date
Application number
HK16100185.7A
Other languages
English (en)
Chinese (zh)
Inventor
Pamela A. LEWIS
William H. Woller
Original Assignee
Macuclear, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49715792&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1212225(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Macuclear, Inc. filed Critical Macuclear, Inc.
Publication of HK1212225A1 publication Critical patent/HK1212225A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HK16100185.7A 2012-06-11 2013-06-06 Therapeutic formulation and methods of treatment HK1212225A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261658304P 2012-06-11 2012-06-11
US61/658304 2012-06-11
PCT/US2013/044617 WO2013188217A1 (en) 2012-06-11 2013-06-06 Therapeutic formulation and methods of treatment

Publications (1)

Publication Number Publication Date
HK1212225A1 true HK1212225A1 (en) 2016-06-10

Family

ID=49715792

Family Applications (1)

Application Number Title Priority Date Filing Date
HK16100185.7A HK1212225A1 (en) 2012-06-11 2013-06-06 Therapeutic formulation and methods of treatment

Country Status (9)

Country Link
US (2) US9254287B2 (enExample)
JP (1) JP2015519398A (enExample)
KR (1) KR20150032552A (enExample)
CN (1) CN104768533A (enExample)
AU (1) AU2013274582A1 (enExample)
HK (1) HK1212225A1 (enExample)
SG (1) SG11201408230VA (enExample)
TW (1) TW201410245A (enExample)
WO (1) WO2013188217A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015164419A1 (en) * 2014-04-22 2015-10-29 Acucela Inc. Pupillometric assessment of retinal pharmacodynamics and responses therefrom
MX2017008737A (es) 2014-12-30 2018-01-25 Cell Cure Neurosciences Ltd Poblaciones de celulas rpe y metodos para generar las mismas.
US20200243170A1 (en) * 2017-10-17 2020-07-30 Apeliotus Technologies, Inc. Functional biomarkers for statin therapy in age-related macular degeneration (amd)
SG11202005795TA (en) * 2017-12-29 2020-07-29 Cell Cure Neurosciences Ltd Retinal pigment epithelium cell compositions
CN112007031A (zh) * 2019-05-30 2020-12-01 杏国新药股份有限公司 眼用制剂
US12109211B2 (en) 2021-12-29 2024-10-08 Endo Operations Limited Hydralazine compositions and methods

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4055645A (en) 1976-02-13 1977-10-25 Merck & Co., Inc. Novel anti-hypertensive compositions
FI873429L (fi) 1986-08-18 1988-02-19 Houston Biotechnology Oftalmologiska kompositioner foer behandling av nervdegenerationer.
US4865599A (en) 1986-08-18 1989-09-12 Houston Biotechnology, Inc. Ophthalmic compositions for treating nerve degeneration
CA1319099C (en) * 1987-01-23 1993-06-15 James A. Nathanson Atriopeptins, guanylate cyclase activators, and phosphodiesterase inhibitors as treatment for glaucoma, hydrocephalus and cerebral edema (cranial fluid volume dysfunction)
US5500230A (en) * 1987-01-23 1996-03-19 The General Hospital Corporation Method for treatment of glaucoma with nitrogen containing guanylate cyclase activators
US5698155A (en) 1991-05-31 1997-12-16 Gs Technologies, Inc. Method for the manufacture of pharmaceutical cellulose capsules
US5252607A (en) 1992-01-24 1993-10-12 Texas A&M University System Treatment of low pressure glaucoma and ischemic retinal degeneration
US5459133A (en) 1992-06-05 1995-10-17 Telor Ophthalmic Pharmaceuticals, Inc. Methods and products for treating presbyopia
TW264385B (enExample) 1993-05-14 1995-12-01 Taiho Pharmaceutical Co Ltd
US5422116A (en) * 1994-02-18 1995-06-06 Ciba-Geigy Corporation Liquid ophthalmic sustained release delivery system
US5596011A (en) 1995-04-06 1997-01-21 Repine; Karen M. Method for the treatment of macular degeneration
CN1216469A (zh) 1996-04-26 1999-05-12 藤泽药品工业株式会社 含有二氢吡啶类化合物的眼组织末梢循环改善剂
US6066675A (en) 1996-09-13 2000-05-23 The Regents Of The University Of California Method for treatment of retinal diseases
ES2317650T3 (es) 1996-10-28 2009-04-16 Senju Pharmaceutical Co., Ltd. Farmacos para mejorar trastornos circulatorios oculares.
EP1058546A4 (en) 1998-03-06 2004-07-28 Univ Texas COMPILATIONS AND METHODS FOR THE TREATMENT OF MACULA DISEASES
US6028099A (en) 1998-03-13 2000-02-22 John Hopkins University, School Of Medicine Use of an inhibitor of the protein tyrosine kinase pathway in the treatment of choroidal neovascularization
CA2363503C (en) 1999-03-05 2009-03-10 University Of Iowa Research Foundation Diagnostics and therapeutics for drusen associated ocular disorders
IL137429A0 (en) 1999-07-28 2001-07-24 Pfizer Prod Inc Methods and compsitions for treating diseases and conditions of the eye
EP1246605A2 (en) 1999-08-10 2002-10-09 The Board Of Regents, The University Of Texas System Facilitating the preservation of sight by increasing optic nerve, choroidal and retinal blood flow
US6692759B1 (en) 2000-06-28 2004-02-17 The Regents Of The University Of California Methods for preparing and using implantable substance delivery devices
US20030171375A1 (en) 2002-02-13 2003-09-11 Brazzell Romulus Kimbro Method for treating ocular neovascular diseases
AU2003287250B9 (en) 2002-10-30 2010-01-28 Ptc Therapeutics, Inc. Identifying therapeutic compounds based on their physical-chemical properties
JP2004250347A (ja) 2003-02-18 2004-09-09 Ajinomoto Co Inc 網膜虚血に基づく疾患の治療および／又は予防剤
US20040214215A1 (en) 2003-03-07 2004-10-28 Yu Ruey J. Bioavailability and improved delivery of alkaline pharmaceutical drugs
US20050059744A1 (en) 2003-09-12 2005-03-17 Allergan, Inc. Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions
US20080300292A1 (en) 2004-11-08 2008-12-04 Nitromed, Inc Nitrosated and Nitrosylated Compounds, Compositions and Methods for the Treatment of Ophthalmic Disorders
EP1858863A1 (en) * 2005-02-28 2007-11-28 Nitromed, Inc. Cardiovascular compounds comprising nitric oxide enhancing groups, compositions and methods of use
US8088773B2 (en) 2005-05-12 2012-01-03 The Texas A&M University System Therapeutic compositions and methods

Also Published As

Publication number Publication date
JP2015519398A (ja) 2015-07-09
TW201410245A (zh) 2014-03-16
US9694010B2 (en) 2017-07-04
SG11201408230VA (en) 2015-01-29
AU2013274582A1 (en) 2015-01-22
KR20150032552A (ko) 2015-03-26
US20160151368A1 (en) 2016-06-02
US20130331393A1 (en) 2013-12-12
WO2013188217A1 (en) 2013-12-19
CN104768533A (zh) 2015-07-08
US9254287B2 (en) 2016-02-09

Similar Documents

Publication Publication Date Title
Casson Medical therapy for glaucoma: A review
KR20210096096A (ko) 노안, 산동, 및 기타 안구 장애의 치료를 위한 방법 및 조성물
JP2023105147A (ja) 眼科用医薬組成物及びそれに関する使用
US9694010B2 (en) Therapeutic formulation and methods of treatment
EA022055B1 (ru) Применение биоусиливающих агентов при перекрестном сшивании роговицы
KR20210005134A (ko) 안구 증상의 치료를 위한 필로카르핀 염산염의 용도
US8097640B2 (en) Prophylactic or therapeutic agent for diabetic maculopathy
CN119745879A (zh) 包含阿西替尼的组合物和治疗眼部疾病的方法
NZ248567A (en) Topical ophthalmic solutions comprising sorbitol, inositol, xylitol and mixtures thereof
Okka et al. Effects of latrunculin B on outflow facility, intraocular pressure, corneal thickness, and miotic and accommodative responses to pilocarpine in monkeys
US20060194874A1 (en) Use of propionyl l-carnitine for the preparation of a medicament for the treatment of glaucoma
EP3380194B1 (en) Composition for blocking angiogenesis
NZ518164A (en) Rivastigmine for the treatment of ocular disorders
CN116650461A (zh) 咖啡酸苯乙酯滴及其眼液在制备治疗糖尿病视网膜病变药物中的应用
Kojima et al. Trans‐Tenon's retrobulbar triamcinolone infusion for myopic choroidal neovascularization
TWI766565B (zh) 用於治療眼疾的組合物及其用途
Willms et al. Minocycline and Diacetyl Minocycline Eye Drops Reduce Ocular Neovascularization in Mice
CN116270442B (zh) 一种用于矫正近距离视力的眼用制剂
RU2770745C1 (ru) Комбинированный способ лечения хориоидальной неоваскуляции всех типов
Deleu et al. Two cases of acute intraocular pressure elevation with dabigatran use in glaucoma patients
Nowak et al. Protective effect on visual functions of long-term use of trimetazidine in treatment of primary open angle glaucoma and degenerative myopia
ALTAŞ Angle Closure Glaucoma and Management in Geriatric Population
Alm et al. A Review of its Pharmacological Properties, Clinical Efficacy and Tolerability in the Management of Primary Open-Angle Glaucoma and Ocular Hypertension